Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Breast Neoplasms × anlotinib × Clear all

Phase

Status

Sponsor Class

OTHER 12 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Nasopharyngeal Carcinoma 1 Head and Neck Neoplasms 1 Breast Neoplasms 1

Interventions

pyrotinib 4 Paclitaxel 4 Capecitabine 4 Vinorelbine 3 Radiotherapy 3 Radiation Dose Hypofractionation 3 Fulvestrant 3 Epirubicin 3 Docetaxel 3 Carboplatin 3 exemestane 2 apatinib 2 Neoadjuvant Therapy 2 Etoposide 2 Cyclophosphamide 2 Albumin-Bound Paclitaxel 2 toripalimab 1 pirarubicin 1 palbociclib 1 icaritin 1 anlotinib 1 Therapeutics 1 Standard of Care 1 Radiation 1 Pemetrexed 1 Methods 1 Granulocyte Colony-Stimulating Factor 1 Doxorubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Completed

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡